In this cross-sectional study of a male population, probable sleep parasomnias, including both SW and RBD, were associated with higher odds of having PD. PD-related neurodegeneration may impair arousal regulation during sleep CLICK TO REVIEW
Visuomotor activity during visually-guided pinch-grip force was measured while controlling for force without visual feedback activity and visual stimuli without force activity in healthy adults. Using physiological noise correction and multiple task repetitions, we demonstrated that visuomotor activity occurs in the inferior portion of the basilar pons and the midbrain. These findings provide direct evidence
There is increasing evidence that heavy metals normally present in the human body in minute concentration also cause accumulation to initiate the free radical formation and affecting the basal ganglia signaling. In this review, we explored how these metals affect brain physiology and their roles in the accumulation of toxic proteins (α-synuclein and Lewy bodies).
REM sleep behavior disorder (RBD) is gaining increasing attention as important prodromal marker for the development of neurodegenerative disorders such as Parkinson’s Disease. However, the clinical relevance of this disorder and its association with other prodromal markers is often underestimated in clinical routine. We here report a case of severe clinical complications following extensive nocturnal
Complications following REM sleep behavior disorder Read More »
Hence, autophagy modulation might provide some interesting cues for the treatment of PD. Additionally, Fibroblast growth factor 21 (FGF21) which is known for its role as a potent regulator of glucose and energy metabolism has also proved to be neuroprotective in various neurodegenerative conditions possibly via mediation of autophagy. CLICK TO REVIEW
Fibroblast growth factor 21 and autophagy: A complex interplay in Parkinson disease Read More »
Parkinson’s disease (PD) is the second most common neurodegenerative disorder characterized by multiple motor and non-motor symptoms, which include, among others, constipation, sleep disturbance, bradykinesia, gait and balance abnormalities, muscle stiffness and resting tremor. The motor symptoms are caused by progressive age-related death of dopaminergic neurons and in the vast majority of patients suffering from
Recently, the protective effects of sulforaphane on brain health were also considerably studied, where the studies have further extended to severalneurological diseases, including Alzheimer’s disease (AD), Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, multiple sclerosis, autism spectrum disorder, and schizophrenia. Animal and cell studies that employ sulforaphane against memory impairment and AD related pre-clinical biomarkers
Higher GMV in the cerebellum may be linked with the abnormal motor behaviors during REM sleep in patients with PD-RBD, and lower GMV and FC in the posterior regions may indicate that PD-RBD correspond to more serious neurodegeneration, especially the visuospatial–executive function impairment and delayed memory impairment. These findings provided new insights to learn more
This review will focus on the most promising marine drugs’ neuro-protective potential for neuro-degenerative disorders, such as Parkinson’s and Alzheimer’s diseases. We will describe these marine compounds’ potential as adjuvant therapies for neuro-degenerative diseases, based on their antioxidant, anti-inflammatory, and anti-apoptotic properties. CLICK TO REVIEW
Benefits under the Sea: The Role of Marine Compounds in Neurodegenerative Disorders Read More »
We present the current status of our knowledge and understanding of the involvement of mitochondrial dysfunction in these diseases and highlight recent advances in novel therapeutic strategies targeting neuronal bioenergetics as potential approach for treating these diseases. CLICK TO REVIEW